Mission Statement

The Locus p38 MAPK inhibitor portfolio will validate the Locus Core Technology and create value for our shareholders and patients with debilitating and life-threatening diseases. Technology collaborations with pharmaceutical partners will support the Locus mission by generating revenue and continuing to advance the technology.